ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

ClearPoint Neuro, Inc.

Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
Full-year 2025 revenue $37.0M, 11th consecutive year of growth; 14% organic YoY increase.
2026 revenue guidance $52-56M, reflecting expected double-digit growth across all four product segments.
Completed IRRAS acquisition in Nov 2025, adding neurocritical care line and $20M additional financing from Oberland Capital.
Cash and equivalents $45.9M at Dec 31, 2025, up from $20.1M a year ago.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported 2026 results: revenue $52.0 - $56.0 million. Guidance initiated.

Period: 2026
Revenue: $52.0 - $56.0 million
Guidance: initiated
Result: guidance update

Exact text from the filing

For 2026, we now expect revenues to be in the range of $52.0 - $56.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $10.4 million. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2025
Revenue: $10.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported fourth quarter revenue of $10.4 million, including $1.2 million of IRRA flow revenue, representing 34% overall growth and 19% year-over-year organic growth compared with the fourth quarter of 2024

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported year ended December 31, 2025 results: revenue $37.0 million. Guidance reaffirmed.

Period: year ended December 31, 2025
Revenue: $37.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported revenue of $37.0 million for the full year 2025, an overall increase of 18% and 14% increase in organic growth over 2024 and signifying the eleventh consecutive year of growth

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-110780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.